Overview#
Piper Sandler has revised its price target for Omnicell Inc. (NASDAQ:OMCL) from $57 to $55, while still maintaining an Overweight rating on the stock. Currently, Omnicell shares are trading at $44.59, indicating potential for growth according to the firm’s target. Other analysts on Wall Street have even higher expectations, with price targets ranging from $52 to $70.
Earnings Performance#
The adjustment in price target comes after Omnicell reported impressive financial results for the first quarter of 2026. The company achieved an adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of $44.7 million, surpassing expectations by $11.7 million and reflecting a 14.4% profit margin. Revenue for the quarter reached $309.9 million, marking a 14.9% increase from the previous year. Both product and service revenues exceeded guidance, contributing to a strong earnings per share (EPS) of $0.55, which was $0.19 above expectations and represented a remarkable 109.6% year-over-year growth.
Revised Guidance#
Following these strong results, Omnicell has raised its guidance for the full year 2026. The company now anticipates an adjusted EBITDA of $160.5 million, up from a previous estimate of $152.5 million. Additionally, the adjusted EPS guidance has been increased to $1.90 from $1.75, reflecting growing confidence in its financial outlook.
Future Expectations#
Omnicell has reiterated its bookings and revenue guidance for 2026, indicating that bookings are expected to be stronger in the latter half of the year as hospitals assess the new Titan XT product launched in late 2025. The positive earnings report and revised forecasts have garnered attention from both analysts and investors, highlighting Omnicell's strong market position and growth potential.